Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Effexor Generic Launches Following ANDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva began shipping the generic of Wyeth's antidepressant Aug. 4.

You may also be interested in...



Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs

Wyeth issues “Dear Healthcare Provider” letter advising that venlafaxine overdose may be associated with increased risk of fatal outcomes.

Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs

Wyeth issues “Dear Healthcare Provider” letter advising that venlafaxine overdose may be associated with increased risk of fatal outcomes.

J&J Lawsuit Claims Wyeth’s Effexor XR Infringes Patent

Johnson & Johnson subsidiary Alza files patent infringement suit against Wyeth.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel